SCYNEXIS, Inc. Forecasted to Earn FY2025 Earnings of $0.07 Per Share (NASDAQ:SCYX)

SCYNEXIS, Inc. (NASDAQ:SCYX) – Stock analysts at Brookline Capital Management lifted their FY2025 earnings estimates for SCYNEXIS in a research report issued on Wednesday, May 8th. Brookline Capital Management analyst K. Dolliver now forecasts that the company will post earnings per share of $0.07 for the year, up from their previous forecast of $0.05. The consensus estimate for SCYNEXIS’s current full-year earnings is ($0.08) per share. Brookline Capital Management also issued estimates for SCYNEXIS’s FY2027 earnings at $0.25 EPS and FY2028 earnings at $0.09 EPS.

SCYNEXIS (NASDAQ:SCYX) last released its earnings results on Thursday, March 28th. The company reported ($0.39) earnings per share (EPS) for the quarter, missing the consensus estimate of $0.31 by ($0.70). The business had revenue of $5.80 million for the quarter, compared to analysts’ expectations of $26.14 million. SCYNEXIS had a net margin of 47.84% and a return on equity of 156.27%.

Several other research analysts have also recently weighed in on SCYX. Cantor Fitzgerald reiterated an “overweight” rating on shares of SCYNEXIS in a research note on Monday, April 1st. StockNews.com cut shares of SCYNEXIS from a “buy” rating to a “hold” rating in a research note on Monday, March 18th.

SCYNEXIS Stock Performance

NASDAQ:SCYX traded up $0.05 during trading hours on Friday, reaching $1.93. The company had a trading volume of 48,614 shares, compared to its average volume of 193,996. The company has a current ratio of 6.26, a quick ratio of 6.26 and a debt-to-equity ratio of 0.17. SCYNEXIS has a 52 week low of $1.35 and a 52 week high of $3.87. The firm has a market cap of $72.92 million, a price-to-earnings ratio of 1.42 and a beta of 1.49. The firm’s 50 day moving average price is $1.57 and its 200-day moving average price is $1.73.

Institutional Inflows and Outflows

Hedge funds have recently bought and sold shares of the stock. Kingdon Capital Management L.L.C. lifted its stake in shares of SCYNEXIS by 19.2% in the fourth quarter. Kingdon Capital Management L.L.C. now owns 2,237,048 shares of the company’s stock worth $4,989,000 after buying an additional 359,900 shares in the last quarter. Avidity Partners Management LP raised its holdings in shares of SCYNEXIS by 9.8% in the 4th quarter. Avidity Partners Management LP now owns 1,448,728 shares of the company’s stock valued at $3,231,000 after buying an additional 129,284 shares during the period. AMH Equity Ltd lifted its holdings in SCYNEXIS by 19.9% during the 1st quarter. AMH Equity Ltd now owns 660,000 shares of the company’s stock worth $970,000 after buying an additional 109,600 shares in the last quarter. Decheng Capital LLC purchased a new position in SCYNEXIS in the fourth quarter valued at $1,239,000. Finally, D.A. Davidson & CO. boosted its holdings in SCYNEXIS by 8.3% in the fourth quarter. D.A. Davidson & CO. now owns 526,490 shares of the company’s stock valued at $1,174,000 after purchasing an additional 40,164 shares during the period. Institutional investors and hedge funds own 54.37% of the company’s stock.

About SCYNEXIS

SCYNEXIS, Inc, a biotechnology company, develops medicines to overcome and prevent difficult-to-treat and drug-resistant infections in the United States. It offers BREXAFEMME for the treatment of patients with vulvovaginal candidiasis (VVC) and recurrent VVC. The company's lead product candidate is Ibrexafungerp, an intravenous drug for the treatment of invasive candidiasis and/or candidemia, refractory invasive fungal infections, invasive aspergillosis, VVC, and recurrent VVC.